EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management

Shai Shimony iD, Maximilian Stahl, Richard M Stone iD

American Journal of Hematology · 2025-05 · 100 (5) · 860-891

DOI: 10.1002/ajh.27625 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 12.02.2025. Verfasst von Shai Shimony und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 251-mal zitiert (Crossref) und nennt 270 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disease Overview Acute myeloid leukemia (AML) is a bone marrow stem cell cancer that is often fatal despite available treatments. Diagnosis, risk assessment, monitoring, and therapeutic management of AML have changed dramatically in the last decade due to increased pathophysiologic understanding, improved assessment technology, and the addition of at least 12 approved therapies. Diagnosis The diagnosis is based on the presence of immature leukemia cells in the blood, and/or bone marrow or less often in extra‐medullary tissues. New biological insights have been integrated into recent classification systems. Risk Assessment The European Leukemia Network has published risk classification algorithms for both intensively and non‐intensively treated patients based on cytogenetic and on molecular findings. Prognostic factors may differ based on the therapeutic approach. Monitoring Our increasing ability to quantify lower levels of measurable residual disease (MRD) potentially allows better response assessment, as well as dynamic monitoring of disease status. The incorporation of MRD findings into therapeutic decision‐making is rapidly evolving. Risk Adapted Therapy The availability of 12 newly approved agents has been welcomed; however, optimal strategies incorporating newer agents into therapeutic algorithms are debated. The overarching approach integrates patient and caregiver goals of care, comorbidities, and disease characteristics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHumansRisk AssessmentNeoplasm, ResidualDisease ManagementPrognosisAlgorithms

Stichwörter der Autor:innen

AML diagnosisAML therapyAML‐molecular diagnosis and therapymeasureable residual disease in AMLneoplasia‐myeloid leukemias and dysplasias

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

ORCID-Profile: Shai Shimony, Richard M Stone

Zitieren

APA

Shimony, S., Stahl, M., & Stone, R. M. (2025). Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management. American Journal of Hematology, 100(5), 860-891. https://doi.org/10.1002/ajh.27625

Vancouver

Shimony S, Stahl M, Stone RM. Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management. American Journal of Hematology. 2025;100(5):860-891. doi:10.1002/ajh.27625

BibTeX
@article{Shimony2025,
  author = {Shimony, Shai and Stahl, Maximilian and Stone, Richard M},
  title = {Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management},
  journal = {American Journal of Hematology},
  year = {2025},
  volume = {100},
  number = {5},
  pages = {860--891},
  doi = {10.1002/ajh.27625}
}
Kostenlos starten →